







an Open Access Journal by MDPI

Advances in Anticancer Drugs and Pharmacotherapy of Cancer

Guest Editors:

Dr. Muhammad Abdul Hadi

Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar

Dr. Md. Sanower Hossain

Centre for Sustainability of Ecosystem and Earth Resources (Pusat ALAM), Universiti Malaysia Pahang, Kuantan 26300, Pahang, Malaysia

Dr. Bey-Hing Goh

Sunway Biofunctional Molecules Discovery Centre, School of Medical and Life Sciences, Sunway University, Petaling Jaya 47500, Selangor Darul Ehsan, Malaysia

Deadline for manuscript

closed (15 October 2023)

Message from the Guest Editors

The pharmacotherapy of cancer has experienced some encouraging novel developments. A new armamentarium of anticancer drugs and their delivery have led to improvements not only in efficacy and safety profiles but also the quality of life both pre and post treatment.

This Special Issue of *Cancers* will cover theoretical and applied aspects of cancer drug discovery, formulation, product development, and clinical practices. Submissions presenting research related to chemical identification, in vitro/in vivo/in silico evaluation of anticancer agents, including natural products, or complementary medicine in original research and review articles are welcome.



submissions:











an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us